Evaluation of the antifungal activity and mode of action of Lafoensia pacari A. St.-Hil., Lythraceae, stem-bark extracts, fractions and ellagic acid;Avaliação da atividade antifúngica e modo de a ção dos extratos da entrecasca, fra ções écido elágico de Lafoensia pacari A. St.-Hil., Lythraceae

Revista Brasileira de Farmacognosia

Volumn 20, Issue 3, 2010, Pages 422-428

  Silva Jr , Iberê F ^a,e   Raimondi, Marcela ^b   Zacchino, Susana ^b   Filho, Valdir Cechinel ^c   Noldin, Vânia F ^c   Rao, Vietla S ^d   Lima, Joaquim C S ^a   Martins, Domingos T O ^a  

^a UNIVERSIDADE FEDERAL DE MATO GROSSO   (Brazil)

^b UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^c UNIVERSIDADE DO VALE DO ITAJAÍ   (Brazil)

^d FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^e UNIVERSITY OF CUIABÁ   (Brazil)

Author keywords

Antifungal activity; Ellagic acid; Extracts and fractions; Inhibition of cell wall; Lafoensia pacari; Mangava brava

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ELLAGIC ACID; ERGOSTEROL; KETOCONAZOLE; LAFOENSIA PACARI EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; BARK; CANDIDA; CELL WALL; CONTROLLED STUDY; FUNGAL CELL; FUNGUS GROWTH; GROWTH INHIBITION; LAFOENSIA PACARI; LYTHRACEAE; MINIMUM INHIBITORY CONCENTRATION; NEUROSPORA CRASSA; NONHUMAN; PLANT STEM; SACCHAROMYCES CEREVISIAE; YEAST;

EID: 77957585978     PISSN: 0102695X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0102-695x2010000300021     Document Type: Article

References (31)

1. Albuquerque DA 1996a. Efeito do extrato etanólico de Lafoensia pacari sobre a peritonite aguda em camundongos. In: Programa e Anais 3a Reunião especial da SBPC "Ecossistemas Costeiros-do conhecimento a gestão", Florianópolis, SC, UFSC.
2. Albuquerque DA 1996b. Efeito do extrato etanólico de Lafoensia pacari sobre a produção de anticorpos in vitro. In: Programa e Anais 3a Reunião especial da SBPC "Ecossistemas Costeiros-do conhecimento a gestão", Florianópolis, SC, UFSC.
3. Barberán J, Mensa J, Fariñas C, Llinares P, Serrano R, Menéndez R, Agustí C, Gobernado M, Azanza J, García Rodríguez J 2008. Recommendations of antifungal treatment in patients with low grade inmunosuppression. Rev Esp Quimioter 21: 127-142.
4. Cechinel Filho V, Yunes RA 1998. Strategies for obtaining pharmacologically active compounds from medicinal plants. Concepts about structural modification for improve the activity. Quim Nova 21: 99-105.
5. Chung JG 1998. Inhibitory actions of ellagic acid on growth and arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients. Microbios 93: 115-127.
6. CLSI (Clinical and Laboratory Standards Institute) formely NCCLS (National Committee for Clinical Laboratory Standards). 2002. Method M27-A2, 2nd ed. Wayne Ed.; 22: 1-29. NCCLS, and method M38-A, 2nd ed, Wayne Ed.; 22: 1-27.
7. CLSI (Clinical Laboratory Standards Institute) formely NCCLS (National Committee for Clinical Laboratory Standards) 2002. Method for antifungal disk diffusion susceptibility testing in yeasts. Approved guideline, vol. M44-A. CLSI, Wayne, Pa.
8. Fromtling RA 1999. Progress in antifungal chemotherapy. Drug News Perspect 12: 557-569.
9. Frost DJ, Brandt KD, Cugier D, Goldman RJ 1995. A whole-cell Candida albicans assay for the detection of inhibitors towards fungal cell wall synthesis and assembly. J Antibiot 48: 306-310.
10. Fukuda D, Nakatsukasa W, Yao R, Hunt A, Gordee R, Zeckner D, Mynderse J 1991. A45507, a complex of fungal cell wall inhibitors produced by a mold. 31st ICAAC Meeting (Chicago, Il, USA) poster # 211.
11. Fukushima Y, Sakagami Y, Marumo S 1993. β-Glucan biosynthesis inhibitors isolated from fungi as hyphal malformation inducer. Bioorg Med Chem Lett 3: 1219-1222.
12. Grau Cerrato S, Torres Rodríguez J, Monterde Junyent J 1996. Situación actual de las infecciones por hongos: ¿son las anfotericinas lipídicas la panacea? Farm Hosp 20: 390-392.
13. Guarim Neto G, Morais RG 2003. Medicinal plants resources in the Cerrado of Mato Grosso State, Brazil: a review. Acta Bot Bras 17: 561-584.
14. Gunji S, Arima K, Beppu T 1983. Screening of antifungal antibiotics according to activities inducing morphological abnormalities. Agric Biol Chem 47: 2061-2069.
15. Kartsonis N, Nielsen J, Douglas C 2003. Caspofungin: the first in a new class of antifungal agents. Drug Resist Update 6: 197-218.
16. Lee SH, Lee JR, Lunde CS, Kubo I 1999. In vitro antifungal susceptibilities of Candida albicans and other fungal pathogens to polygodial, a sesquiterpene dialdehyde. Planta Med 65: 204-208.
17. Lima MR, de Souza Luna J, dos Santos AF, de Andrade MC, Sant'Ana AE. Genet JP, Marquez B, Neuville L, Moreau N. 2006. Anti-bacterial activity of some Brazilian medicinal plants. J Ethnopharmacol 21: 137-147.
18. Matos FJA 1988. Introdução à fitoquímica experimental. Imprensa Universitária da Universidade Federal do Ceará, Fortaleza.
19. Mota Menezes V, Atallah AN, Lapa AJ, Catapani WR 2006. Assessing the therapeutic use of Lafoensia pacari St. Hil. extract (mangava-brava) in the eradication of Helicobacter pylori: double-blind randomized clinical trial. Helicobacter 11: 188-195.
20. Müller V, Chávez JH, Reginatto FH, Zucolotto SM, Niero R, Navarro D, Yunes RA, Schenkel EP, Barardi CR, Zanetti CR, Simões CM 2007. Evaluation of antiviral activity of South American plant extracts against herpes simplex virus type 1 and rabies virus. Phytother Res 21: 970-974.
21. Murakami S, Isobe Y, Kijima H, Nagai H, Muramatu M, Otomo S 1991. Inhibition of gastric H+, K(+)-ATPase and acid secretion by ellagic acid. Planta Med 57: 305-308.
22. Onishi J, Meinz M, Curotto J, Dreikorn S, Rosenbach M, Douglas C, Abruzzo G, Flattery A, Kong L, Cabello A, Vicente F, Pelaez F, Diez M, Martin I, Bills G, Giacobbe R, Dombrowski A, Schwartz R, Morris S, Harris G, Tsipouras A, Wilson K, Kurtz M 2000. Discovery of novel antifungal (1,3)β-D-glucan synthase inhibitors. Antimicrob Agents Chemother 44: 368-377.
23. Quindos G 2002. Las micosis en el amanecer del siglo XXI. Rev Iberoam Micol 19: 1-4.
24. Rogerio AP, Sa-Nunes A, Albuquerque DA, Anibal FF, Medeiros AI, Machado ER, Souza AO, Prado JCJ, Faccioli LH 2003. Lafoensia pacari extract inhibits IL-5 production in toxocariasis. Parasite Immunol 25: 393-400.
25. Rogerio AP, Fontanari C, Borducchi E, Keller AC, Russo M, Soares EG, Albuquerque DA, Faccioli LH 2008a. Antiinflammatory effects of Lafoensia pacari and ellagic acid in a murine model of asthma. Eur J Pharmacol 580: 262-270.
26. Rogerio AP, Fontanari C, Melo MC, Ambrosio SR, de Souza GE, Pereira OS, França SC, da Costa FB, Albuquerque DA, Faccioli LH 2006. Anti-inflammatory, analgesic and anti-oedematous effects of Lafoensia pacari extract and ellagic acid. J Pharm Pharmacol 58: 1265-73.
27. Rogerio AP, Sá-Nunes A, Albuquerque DA, Soares EG, Faccioli LH 2008b. Anti-eosinophilic effect of Lafoensia pacari in toxocariasis. Phytomedicine 15: 348-57.
28. Solon S, Lopes L, Teixeira de Souza PJ, Schmeda-Hirschmann G 2000. Free radical scavenging activity of Lafoensia pacari. J Ethnopharmacol 72: 173-178.
29. Solon S 1999. Alguns aspectos Químico-Farmacológicos da Entrecasca do Caule da Lafoensia pacari St. Hil. (Mangava-brava, Lythraceae). Cuiabá, 110 p. Dissertação de Mestrado, Programa de Pós-graduação em Saúde e Ambiente, Universidade Federal de Mato Grosso.
30. Tamashiro-Filho P 1999. Avaliação da atividade antiúlcera do extrato bruto metanólico de Lafoensia pacari St. Hil. (mangava-brava). Cuiabá, 129 p. Dissertação de Mestrado, Programa de Pós-graduação em Saúde e Ambiente, Universidade Federal de Mato Grosso.
31. Zacchino S, Yunes R, Cechinel V, Enriz RD, Kouznetsov V, Ribas JC 2003. The need for new antifungal drugs: Screening for antifungal compounds with a selective mode f action with emphasis on the inhibitors of the fungal cell wall. In: Mahendra Rai, Donatella Mares (Eds.) Plant Derived Antimycotics, Haworth Press (New York); 1-47.